e-therapeutics plc announced that it has entered into a collaboration agreement with C4X Discovery Holdings PLC to combine its drug discovery platform with the latter's genomics capabilities. The collaboration will aim to identify novel intervention strategies that have potential in the treatment of Parkinson's disease ("PD"), a debilitating and progressive neurological disease where there remains a significant unmet medical need. The collaboration is based on leveraging the power of e-therapeutics' proprietary Network-Driven Drug Discovery (NDD) platform with C4XD's Taxonomy3 technology, C4XD's innovative DNA-based target identification platform that utilises human genetic datasets to identify novel patient-specific targets.

Taxonomy3 has already identified 180 novel disease-associated genes for PD. Using these results, e-therapeutics will apply its pioneering NDD platform to derive new insights into the corresponding cellular mechanisms in order to understand their interplay and centrality in the pathology of the disease. Results generated in the collaboration shall be jointly owned by e-therapeutics and C4XD.

The financial terms of the agreement are undisclosed.